AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KAUG 133 min read$VNRX

VOLITIONRX LTD (VNRX): Results of Operations and Financial Condition

VOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Friday, August 14 at 8:30 a.m. U.S. Eastern Time Henderson, Nevada, August 13, 2026 /PRNewswire/ -- Volit

Original reporting
SEC EDGAR 8-K
Published Aug 13, 2026, 8:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$VNRX
Neutral
low confidence
Mentioned
$VNRX
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$VNRXNeutralLow
01

Why it matters

The filing itself is a procedural disclosure that typically precedes market repricing once investors digest the actual earnings metrics and any guidance or operational updates in the attached press release.

02

Market read

This sets up an earnings-event window for VNRX, but the provided text does not include the figures needed to forecast direction.

03

What to watch

The key driver is likely the content of Exhibit 99.1 (financials and business updates). The scraped body omits those details, so the real trading signal may be missed.

Relevance 7/10Novelty 2/10Timing: Filed Aug 13, 2026, with conference call scheduled for Aug 14, 2026 premarket/market hours depending on local timing.

Background

The SEC 8-K (Item 2.02) states VolitionRx issued a press release with financial results and business updates for the quarter ended June 30, 2026, and confirmed a conference call for Aug 14, 2026.

Company-level read

Ticker impact

$VNRXNeutralLow confidence
Context

VolitionRx filed an 8-K furnishing its quarter ended June 30, 2026 results press release and scheduled an Aug 14, 2026 call.

Expected impact

Near-term volatility possible into the Aug 14 conference call, but direction cannot be inferred from the provided text.

Evidence & confidence

The filing confirms the existence of a results press release and call timing, yet provides no numbers, guidance, or qualitative outcomes in the article body.

Market effects

Sector

Limited read-through because the article body does not disclose trial, regulatory, or product milestones.

Regional

Minimal, as this is a single-company SEC filing without disclosed macro drivers.

Global

Low, no cross-border deal, regulation, or supply-chain event is described.

Counterpoint

What could challenge this read

Traders may overreact to the mere presence of an 8-K, but without the actual results/guidance in the text, the filing alone is not a directional catalyst.

Key entities

  • issuer
    VolitionRx Limited

    Company filing the 8-K and furnishing Exhibit 99.1 with quarterly results and business updates.

  • executive
    Cameron Reynolds

    CEO and President signing the 8-K.

Read at source← All news

Related articles

AUG 26
$VNRXMedAI 8/10

Volition Validates Nu.Q NETs Biomarker In Sepsis; Stock Down

VolitionRx (VNRX) validated its Nu.Q NETs biomarker for sepsis, predicting mortality and kidney therapy needs. Published in Critical Care Medicine, the study found higher levels in septic shock, aiding risk stratification. The $0.34 stock fell 10.37%, amid a $2.8B market opportunity. The company completed a 1-for-20 reverse stock split on April 28, 2026.

rttnews.com2 min
AUG 13
$VNRXMed

VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update

VolitionRx Limited (NYSE American: VNRX) reported Q2 2026 revenue of about $0.4 million, flat versus Q2 2025, and first-half 2026 revenue of $1.4 million, up 112% year over year. Operating expenses fell 32% and operating loss was $4.2 million. The company said it is discussing licensing deals, including a Sysmex collaboration, and expects a $5 million milestone from a Nu.Q Vet feline assay peer review.

prnewswire.com4 min
SEP 22
$AZOMedAI 8/10

AutoZone Q4 EPS Hits $56.05 as Annual Sales Reach $20.3bn

AutoZone (AZO) reported Q4 2026 EPS of $56.05, up from $48.71 a year earlier, with net sales of $6.6bn, a 5.6% increase. Full-year sales reached $20.3bn, up 7.4%. Gross margin rose to 53.3%, boosted by tariff refunds and LIFO benefits. The company opened 175 new stores, ending the year with 8,031 locations. Shares rose 4.33% post-earnings.

financial-news.co.uk2 min
SEP 22
$AZOHighAI 8/10

Why AutoZone (AZO) Stock Is Trading Up Today

AutoZone (AZO) shares rose 6.1% after reporting Q4 EPS of $56.05, beating estimates. Net sales were $6.6B, missing expectations. Same-store sales grew 1.6%, and gross margin expanded 182 bps to 53.3%. The company's stock has had limited volatility, with today's move being notable. AZO is down 9.9% YTD, trading 30.6% below its 52-week high.

financialcontent.com2 min
SEP 22
$AMGNMedAI 8/10

Amgen Hits Primary Endpoint In Sjögren's Trial, But Approval Filing Awaits Another Trial Data - Amgen (NA

Amgen (AMGN) reported positive results from its Phase 3 OASIZ 301 trial for dazodalibep in treating Sjögren’s disease, meeting the primary endpoint. The study showed statistically significant improvements in disease activity scores. Adverse events were low and similar to placebo. Amgen plans to share full data at a future conference and awaits results from another trial, OASIZ 303, for potential FDA filing. Shares rose 3.54% to $407.08. Analysts expect two positive trials for approval.

benzinga.com4 min